
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.
Our protease engineering platform generated two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; a discovery stage Factor IX gene therapy construct – CB 2679d-GT – for Hemophilia B, and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.
Up to 90% verified emails and mobile numbers, refreshed weekly.
Catalyst Biosciences operates in the Biotechnology Research industry and is headquartered in United States.
Catalyst Biosciences has approximately 51-200 employees employees.
Catalyst Biosciences is based in South San Francisco, CA, United States.
Yes. Catalyst Biosciences is a publicly traded company.
You can reach Catalyst Biosciences’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.
Our team will be in touch soon. If you have any questions, please email us at info@scalelist.com
Just a few more details..
Our team will be in touch soon. If you have any questions, please email us at arnaud@scalelist.com